Biological therapy in chronic rhinosinusitis with nasal polyposis: a retrospective study
DOI:
https://doi.org/10.34631/sporl.3129Keywords:
Chronic rhinosinusitis, Monoclonal antibodies, Dupilumab, Mepolizumab, Sniffin’ sticksAbstract
Objectives: To describe the case series of patients with CRSwNP under biological therapy in a tertiary hospital.
Study Design: Retrospective observational study.
Material and Methods: Patients with CRSwNP who started biological therapy between April 2023 and December 2024 were included. Patients were evaluated at weeks 0, 4 and 16. Therapeutic response was assessed according to the EPOS/EUFOREA 2023 criteria, using the NPS, NOSE, SNOT-22, VAS for smell and nasal obstruction, and the Sniffin’ Sticks test. Statistical analysis was performed using Friedman and Wilcoxon tests (p<0.05).
Results: A total of 23 patients under treatment with Dupilumab or Mepolizumab were included. There was a significant reduction in NPS, SNOT-22, olfaction and nasal obstruction VAS (p<0.0001) and an increase in Sniffin’ Sticks scores (p<0.001) between week 0 and week 16 of treatment.
Conclusions: Biological therapy showed symptomatic efficacy and improved quality of life in CRSwNP patients who do not respond to conventional therapy.
Downloads
References
Fokkens W, Van Der Lans R, Reitsma S. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021 May;21(5):575-585. doi: 10.1080/14712598.2021.1901881.
Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P. et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023 Jun 1;61(3):194-202. doi: 10.4193/Rhin22.489.
Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN. et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020 Oct 29;6(1):86. doi: 10.1038/s41572-020-00218-1.
Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S. et al. The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol. 2024 Apr 16:15:1356298. doi: 10.3389/fimmu.2024.1356298.
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
Infarmed. Autoridade Nacional do Medicamento e Produtos de Saúde I.P. Autorização de introdução no mercado [Internet]. Lisboa: Infarmed; [cited 2025 Apr 15]. Available from: https://www.infarmed.pt/web/infarmed/entidades/medicamentos-uso-humano/autorizacao-de-introducao-no-mercado
Sanofi. A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids [Internet]. clinicaltrials.gov; 2019 Jul. Report No.: NCT02912468. [cited 2025 Apr 15]. Available from: https://fdaaa.trialstracker.net/trial/NCT02912468/
Sanofi. A randomized, double-blind, 52-week, placebo controlled efficacy and safety study of dupilumab, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids [Internet]. clinicaltrials.gov; 2019 Oct. Report No.: NCT02898454. [cited 2025 Apr 15]. Available from: https://fdaaa.trialstracker.net/trial/NCT02898454/
Hoffmann-La Roche. A phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with chronic rhinosinusitis with nasal polyps [Internet]. clinicaltrials.gov; 2020 Mar. Report No.: NCT03280537. [cited 2025 Apr 15]. Available from: https://fdaaa.trialstracker.net/trial/NCT03280537/
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE. et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7.
Silver J, Packnett E, Park J, Deb A. Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study. Allergy Asthma Clin Immunol. 2023 Dec 8;19(1):104. doi: 10.1186/s13223-023-00855-7.
Soler ZM, Patel ZM, Mullol J, Mattos J, Nash S, Xia C. et al. Association between smell loss, disease burden, and dupilumab efficacy in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2025 Jan;39(1):6-12. doi: 10.1177/19458924241274501.
Galletti C, Ragusa M, Sireci F, Ciodaro F, Barbieri MA, Giunta G. et al. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience. Am J Otolaryngol. 2024 Jan-Feb;45(1):104106. doi: 10.1016/j.amjoto.2023.104106.
Book R, Eligal S, Tal Y, Eliashar R. Biological treatment for uncontrolled chronic rhinosinusitis with nasal polyps: preliminary real-world results from a Tertiary Medical Center. J Clin Med. 2023 May 25;12(11):3671. doi: 10.3390/jcm12113671.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Beatriz Nicolau, Cláudia Geraldes, André Alves Pereira, Tiago Infante Velada, Jorge Mexia, Herédio de Sousa
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
